Denali Advisors LLC decreased its holdings in DaVita Inc. (NYSE:DVA – Free Report) by 55.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,528 shares of the company’s stock after selling 3,113 shares during the quarter. Denali Advisors LLC’s holdings in DaVita were worth $562,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in the business. NewEdge Advisors LLC grew its stake in shares of DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of DaVita by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after acquiring an additional 28,739 shares in the last quarter. Cerity Partners LLC boosted its holdings in DaVita by 7.0% in the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after purchasing an additional 172 shares during the period. Bank of Nova Scotia grew its stake in DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after purchasing an additional 176 shares in the last quarter. Finally, Natixis grew its stake in DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after purchasing an additional 3,264 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Finally, UBS Group boosted their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $221.75.
Insider Transactions at DaVita
In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.90% of the stock is owned by corporate insiders.
DaVita Stock Down 1.0%
Shares of DVA opened at $175.54 on Friday. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of 14.36, a price-to-earnings-growth ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The stock has a 50 day moving average price of $215.64 and a 200 day moving average price of $181.58.
DaVita (NYSE:DVA – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts anticipate that DaVita Inc. will post 14.57 EPS for the current fiscal year.
DaVita Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Further Reading
- Five stocks we like better than DaVita
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
